Subscribe To
LIAN / LianBio to Participate in Upcoming Investor Conferences

LIAN News

By The Motley Fool
October 27, 2023
Why LianBio Stock Is Shooting Through the Roof This Week
LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianB more_horizontal

By InvestorPlace
October 24, 2023
Why Is LianBio (LIAN) Stock Up 130% Today?
Shares of LianBio (NASDAQ: LIAN ) — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inf more_horizontal

By The Motley Fool
October 24, 2023
Why LianBio Stock Is Skyrocketing Today
LianBio entered into a deal to give Bristol Myers Squibb exclusive rights for mavacemten in China and other Asian markets. The small drugmaker will re more_horizontal

By GlobeNewsWire
June 1, 2023
LianBio to Participate in Upcoming Investor Conferences
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovativ more_horizontal

By Zacks Investment Research
December 20, 2022
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is elig more_horizontal

By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal

By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal

By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal